About Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin tincidunt elit id elit molestie, quis laoreet nisi convallis. Praesent sapien magna, viverra vel ante vel, pretium vestibulum ante. Aenean volutpat maximus nisi, vitae pulvinar orci convallis eget. Mauris iaculis pretium auctor. Donec tempus risus libero, eu tincidunt lorem porta eu. Aliquam erat volutpat. In ultrices iaculis tristique.
Featured
View More News
Events
View More EventsServices
Our Providers
Patient Resources
Patient resource lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin tincidunt elit id elit molestie, quis laoreet nisi convallis. Praesent sapien magna, viverra vel ante vel, pretium vestibulum ante. Aenean volutpat maximus nisi, vitae pulvinar orci convallis eget. Mauris iaculis pretium auctor. Donec tempus risus libero, eu tincidunt lorem porta eu. Aliquam erat volutpat. In ultrices iaculis tristique.
Forms
Additional Resources
Frequently Asked Questions
Research
Research lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin tincidunt elit id elit molestie, quis laoreet nisi convallis. Praesent sapien magna, viverra vel ante vel, pretium vestibulum ante. Aenean volutpat maximus nisi, vitae pulvinar orci convallis eget. Mauris iaculis pretium auctor. Donec tempus risus libero, eu tincidunt lorem porta eu. Aliquam erat volutpat. In ultrices iaculis tristique.
Clinical Trials
The main purpose of this study is to learn how well tumors that have specific genetic changes (mutations) respond to drugs that “target” those changes. This combination of a tumor with a mutation and a drug that aims at that mutation is called a “match.” There are two steps for participants in this study.
The overall goal of this study is to compare the effects, good and/or bad of the study drugs brentuximab vedotin and nivolumab (Bv-NIVO) against the standard therapy of chemotherapy with or without radiation for people with Hodgkin Lymphoma (HL) to find out which is better.
Treatment for Primary Mediastinal (Thymic) Large B-Cell Lymphoma (PMBCL) involves chemotherapy combined with an immunotherapy called rituximab. This combination is also known as the chemo-immunotherapy backbone. There are two types of chemo-immunotherapy backbone treatments for PMBCL: either R-CHOP or DA-EPOCH-R.
